Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal (Q38207555)

31 August 2017

title

Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal (English)

1 reference

31 August 2017

1 reference

Lawrence Steinman

1

1 reference

31 August 2017

publication date

1 May 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

58

1 reference

31 August 2017

issue

2-3

1 reference

31 August 2017

page(s)

307-314

1 reference

Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Genetic control of the antibody response in inbred mice. Transfer of response by spleen cells and linkage to the major histocompatibility (H-2) locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

A cell-surface molecule involved in organ-specific homing of lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Antigen-reactive T cell clones. I. Transcomplementing hybrid I-A-region gene products function effectively in antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Disappearance and reappearance of B cells after in vivo treatment with monoclonal anti-I-A antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Selection for T-cell receptor Vβ–Dβ–Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

T cell recognition as the target for immune intervention in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Natalizumab: bench to bedside and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

The discovery of natalizumab, a potent therapeutic for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Immunology of relapse and remission in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Angiotensin II sustains brain inflammation in mice via TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Isolation of cDNA clones encoding T cell-specific membrane-associated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8509-0

Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies

21 January 2018

1 reference

12 December 2020

Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker

1 reference

12 December 2020

Comparison of rat and rat-mouse chimeric anti-murine CD4 antibodies in vitro. Chimeric antibodies lyse low-density CD4+ cells

1 reference

12 December 2020

Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop

1 reference

12 December 2020

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

12 December 2020

The road not taken: antigen-specific therapy and neuroinflammatory disease

1 reference

12 December 2020

Successful treatment of EAE in rhesus monkeys with MHC class II specific monoclonal antibodies

1 reference

12 December 2020

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

1 reference

12 December 2020

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

12 December 2020

Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody

1 reference

12 December 2020

10.1007/S12026-014-8509-0

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1026848228

0 references

1 reference